| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Tessier-Lavigne Marc is a Director at Denali Therapeutics Inc. with holdings across 2 companies. Recent SEC Form 4 filings include 0 buys and 44 sells.
Estimated insider holdings value: $45.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 9, 2021 | REGN Regeneron Pharmaceuticals, Inc. | Director | Sale+OE | 3,784 | $665.00 | $2,516,360.00 | -64.6% | -6.4% | +12.7% | |
| Sep 13, 2021 | REGN Regeneron Pharmaceuticals, Inc. | Director | Sale+OE | 12,750 | $641.71 | $8,181,826.81 | -11.1% | +3.2% | +9.7% | |
| Jun 7, 2021 | DNLI Denali Therapeutics Inc. | Director | Sale+OE | 94,378 | $70.35 | $6,639,523.01 | -1.8% | -24.9% | -65.0% | |
| May 24, 2021 | DNLI Denali Therapeutics Inc. | Director | Sell | 46,763 | $60.11 | $2,811,048.43 | -0.9% | -16.0% | -62.2% | |
| May 3, 2021 | DNLI Denali Therapeutics Inc. | Director | Sell | 3,237 | $60.11 | $194,588.72 | - | -13.4% | -56.2% | |
| Apr 1, 2021 | DNLI Denali Therapeutics Inc. | Director | Sell | 50,000 | $56.62 | $2,831,070.88 | -0.6% | +40.2% | -37.4% | |
| Mar 1, 2021 | DNLI Denali Therapeutics Inc. | Director | Sell | 100,000 | $66.22 | $6,622,207.14 | -0.5% | - | - | |
| Jun 16, 2020 | DNLI Denali Therapeutics Inc. | Director | Sell | 400,000 | $26.10 | $10,440,000.00 | -12.7% | - | - | |
| May 6, 2020 | REGN Regeneron Pharmaceuticals, Inc. | Director | Sale+OE | 15,000 | $563.97 | $8,459,496.00 | -32.0% | - | - | |
| Feb 13, 2020 | REGN Regeneron Pharmaceuticals, Inc. | Director | Sale+OE | 14,279 | $400.01 | $5,711,710.99 | -37.5% | - | - |